• About Us
    • Our Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Approach
    • Focus Areas
    • Collaborations
  • Our Science
    • Our Pipeline
    • QLS-111
    • Publications & Posters
  • News & Events
  • Careers
  • Contact Us
  • Skip to main content
Qlaris Bio

Qlaris Bio

Careers Contact Us

Our science is visionary.
Our commitment is relentless.

Our mission is to
preserve vision and
prevent blindness.

About Us

Qlaris Bio is a clinical stage biotechnology company founded on a relentless commitment to develop innovative first-in-class therapies that can make a truly impactful change for patients suffering from serious and debilitating ophthalmic diseases.

Learn More

Our Approach

We are exploring novel mechanisms of action to address the largest unmet needs in ophthalmology.

Learn More

Our Science

Our lead asset, QLS-111, has a unique vasodilatory mechanism of action and is designed to lower intraocular pressure (IOP) by reducing episcleral venous pressure (EVP) and distal outflow resistance beyond the trabecular meshwork. By reducing EVP, and distal outflow resistance, QLS-111 has the potential to enable the achievement of lower IOP targets than available therapies currently allow.

QLS-111 is currently in development for the treatment of Normal Tension Glaucoma, Primary Open-Angle Glaucoma, Ocular Hypertension, and elevated IOP associated with rare diseases such as Sturge-Weber Syndrome.

Learn More

Recent News See All News

Qlaris Bio Named 2022 Scrip Awards Finalist for Biotech Company of the Year 

newsOctober 4, 2022

Annual awards program recognizes innovations and achievements in global biopharma Wellesley, Mass., September 28, 2022 – Qlaris Bio, Inc, a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today it has been named a finalist in the WuXi AppTec’s Biotech Company of the Year category of the 2022 Scrip Awards. Qlaris has seen […]

Read More

Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101

newsMay 18, 2022

Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101  Findings from First-in-Human Study Support Continued Clinical Development of Investigational IOP-lowering Therapy; New Trials Planned as Complementary Glaucoma Treatment and in Rare Pediatric Indication  Wellesley, Mass., May 18, 2022 – Qlaris Bio, Inc. (the “Company” or “Qlaris”), […]

Read More

Upcoming Events See All Events

There are no posts to display.

Qlaris Bio, Inc. © 2023 All Rights Reserved Privacy Policy | Terms of Use | Accessibility Statement